Meta Information
ID:rapamycin-topical
Name:Topical Rapamycin
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-07-02T07:35:59Z
Model
phase-b-topical-claude-opus-4.8
Interactions
Target id:
/condition/skin-infection
Target name:
Local skin infection
Severity:
minor
Interaction type:
adverse
Nature:
conditional
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Topical rapamycin (an mTOR inhibitor) mildly suppresses local immune activity, which could theoretically slow clearance of a skin infection at the site.
Actionable advice:
Application to actively infected skin is best avoided; systemic interactions are minimal at topical doses.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / dermatologic practice (no single primary source quoted)
Exact phrase from label:
Local mTOR inhibition may modestly impair local immune response; systemic absorption is low (unlike oral sirolimus). Mechanistic.
Label source:
Class inference
Action type:
monitor
Target id:
/class/topical-medications-general
Target name:
Other topical actives
Severity:
minor
Interaction type:
informational
Nature:
relative
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Topical rapamycin is usually used alone on the treatment area; layering many actives may increase irritation.
Actionable advice:
Introduce alongside other actives gradually; apply to clean skin.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / dermatologic practice (no single primary source quoted)
Exact phrase from label:
Topical layering can compound irritation; low systemic interaction risk. Practical.
Label source:
Class inference
Action type:
informational_none